KASINGER JAMES R. 4

What Happened

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics (CRSP), received a grant of 17,000 restricted stock units (RSUs) on May 29, 2026. The award was reported as a derivative award (transaction code A) with no cash paid (price reported $0.00).
• Each RSU represents a contingent right to one common share; 100% of the award vests on November 29, 2028 (per footnotes). Because these are RSUs, they are not immediately tradable shares until they vest and are settled.

Key Details

• Transaction date: 2026-05-29; filing date: 2026-06-02 (Form 4 filed within the SEC’s two-business-day window).
• Grant: 17,000 RSUs @ $0.00 (award/derivative).
• Vesting: 100% of the RSUs vest on November 29, 2028.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 confirms each RSU converts to one common share upon settlement; F2 specifies the grant date and vesting schedule.

Context

• RSU grants are a form of equity compensation intended to align executive incentives over time; they are not outright purchases or sales and do not signal an immediate buy/sell of company stock.
• These RSUs will result in actual shares only if and when they vest (Nov 29, 2028) and any tax-withholding or settlement steps occur; no sale or exercise occurred at grant.